首页> 外文期刊>Journal of pain & palliative care pharmacotherapy >The challenge of pain management in patients with myasthenia gravis.
【24h】

The challenge of pain management in patients with myasthenia gravis.

机译:重症肌无力患者疼痛管理的挑战。

获取原文
获取原文并翻译 | 示例
       

摘要

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. The complexity of the disease and its treatments make MG patients particularly susceptible to adverse effects of drugs. MG is not a painful condition; however, as pain management armamentarium includes drugs from diverse pharmacological groups and with potential for drug-drug interactions, managing pain in patients with MG can be challenging. The underlying disease and the concomitant medications of each patient must be considered and the analgesic treatment individualized. This review presents an update on the various aspects of pain pharmacotherapy in patients with MG, focusing primarily on medications used to treat chronic pain. Drugs discussed are opioids, nonsteroidal anti-inflammatory drugs, antidepressants, anticonvulsants, muscle relaxants, benzodiazepines, intravenous magnesium, and local anesthetics. Drug interactions with agents used for MG treatment (acethylcholinesterase inhibitors, corticosteroids, immunosuppressants) and plasmapheresis are discussed. The clinical usefulness and limitations of each of the drug classes and agents are described.
机译:重症肌无力(MG)是神经肌肉接头的一种自身免疫性疾病。这种疾病的复杂性及其治疗方法使MG患者特别容易受到药物不良反应的影响。 MG不是痛苦的状况;但是,由于疼痛管理武器库包括来自不同药理学组的药物,并且具有药物与药物相互作用的潜力,因此在MG患者中管理疼痛可能具有挑战性。必须考虑每位患者的潜在疾病和随之而来的药物,并对镇痛药进行个体化治疗。这篇综述介绍了MG患者疼痛药物治疗各个方面的最新情况,主要侧重于用于治疗慢性疼痛的药物。讨论的药物包括阿片类药物,非甾体抗炎药,抗抑郁药,抗惊厥药,肌肉松弛药,苯二氮卓类药物,静脉注射镁和局部麻醉药。讨论了与用于MG治疗的药物(乙酰胆碱酯酶抑制剂,皮质类固醇,免疫抑制剂)和血浆置换的药物相互作用。描述了每种药物类别和药剂的临床实用性和局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号